NEW YORK, August 16, 2017 /PRNewswire/ --
If you want a Stock Review on DEPO, SGYP, NVO, or SCLN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com has issued research reports on Depomed Inc. (NASDAQ: DEPO), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), and SciClone Pharmaceuticals Inc. (NASDAQ: SCLN). Companies in the Drug Manufacturers space are engaged in one or more of the following: manufacturing biological and medical products; processing botanical drugs and herbs; isolating active medical principles from botanical drugs and herbs; and manufacturing pharmaceutical products intended for internal and external consumption. Daily Stock Tracker published free research reports on these stocks today at:
Newark, California headquartered Depomed Inc.'s shares gained 0.33%, closing Tuesday's trading session at $6.15. The stock recorded a trading volume of 1.74 million shares. The Company's shares are trading 38.50% below their 50-day moving average. Additionally, shares of Depomed, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the US, have a Relative Strength Index (RSI) of 19.61.
On August 07th, 2017, Depomed reported financial results for Q2 ended June 30th, 2017. Highlights for the quarter included: revenues of $100 million and cash and marketable securities of $117 million. For Q2 2017, GAAP net loss was ($27) million; non-GAAP adjusted earnings were $5 million; and non-GAAP adjusted EBITDA was $28 million.
On August 08th, 2017, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with a decrease of the target price from $13 a share to $10 a share. See our free and comprehensive research report on DEPO at:
On Tuesday, shares in New York headquartered Synergy Pharmaceuticals Inc. recorded a trading volume of 5.60 million shares, which was above their three months average volume of 4.80 million shares. The stock declined 1.70%, ending the day at $2.89. The Company's shares are trading below their 50-day moving average by 29.90%. Furthermore, shares of Synergy Pharma, which focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders, have an RSI of 19.95.
On August 09th, 2017, Synergy Pharma reported its financial results for the three months ended June 30th, 2017. In Q2 2017, net sales were $2.3 million; R&D expenses were approximately $22.3 million; and SG&A expenses were approximately $50.7 million. As of June 30th, 2017, the Company had approximately $82 million cash and cash equivalents.
On August 10th, 2017, research firm Rodman & Renshaw reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $18 a share to $15 a share. SGYP free research report is just a click away at:
Bagsvaerd, Denmark headquartered Novo Nordisk A/S' stock finished the day 0.40% higher at $45.51 with a total trading volume of 1.33 million shares. The Company's shares have advanced 5.62% in the last one month, 11.41% in the previous three months, and 26.91% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 5.91% and 20.77%, respectively. Additionally, shares of Novo Nordisk, which engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide, have an RSI of 64.11. Sign up for your complimentary report on NVO at:
Shares in Foster City, California headquartered SciClone Pharmaceuticals Inc. ended yesterday's session flat at $11.05. The stock recorded a trading volume of 243,707 shares. The Company's shares have advanced 0.45% in the last one month, 13.92% over the previous three months, and 2.31% since the start of this year. The stock is trading 1.50% and 8.96% above its 50-day and 200-day moving averages, respectively. Moreover, shares of SciClone Pharma, which provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People's Republic of China, the US, and Hong Kong, have an RSI of 53.32.
On August 09th, 2017, SciClone Pharma reported financial results for the quarter ended June 30th, 2017. For Q2 2017, revenues were $44.5 million; GAAP diluted EPS was $0.23; and non-GAAP diluted EPS was $0.30. As of June 30th, 2017, cash and cash equivalents totaled $157.3 million compared to $134.4 million as of December 31st, 2016. Register for free on DailyStockTracker.com and download the latest research report on SCLN at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA